Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1401-1420 of 1,694 trials

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Psilocybin for Chemotherapy-Induced Pain Relief

We are exploring whether psilocybin can help reduce chronic pain for patients recovering from chemotherapy. The goal is to see if it improves daily activities affected by pain.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncologyOtolaryngology

ORE-001 for Underweight Elderly Individuals

We are studying whether ORE-001, an oral medication, can help underweight elderly people increase their food intake and improve their health. The trial compares its effects to a placebo to assess safety and overall well-being.

Underweight3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyGastroenterologyInternal Medicine

Delayed Sleep-Wake Phase Disorder: Tasimelteon Study

We are investigating whether tasimelteon can help people with Delayed Sleep-Wake Phase Disorder fall asleep faster and improve their overall sleep quality compared to a placebo.

Delayed Sleep-Wake Phase Disorder≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Systemic Sclerosis: Nintedanib and Tocilizumab Study

We are testing a combination of nintedanib and tocilizumab for patients with systemic sclerosis and interstitial lung disease. The goal is to see if this new treatment is more effective than standard therapies.

Systemic SclerosisSystemic Sclerosis with Interstitial Lung Disease1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPulmonologyRheumatology

Advanced Non-Small Cell Lung Cancer: MaaT033 and Cemiplimab

We are studying a new treatment combining fecal microbiotherapy with Cemiplimab for patients with advanced NSCLC who have not responded to previous therapies. This trial aims to see if this combination can improve disease control and overall health compared to standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Citalopram for Reflux Hypersensitivity and Functional Heartburn

We are studying whether adding citalopram to existing treatments helps patients with reflux hypersensitivity or functional heartburn who still have symptoms. This trial aims to improve symptom relief for those not fully responding to current therapies.

Gastroesophageal Reflux Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPsychiatry

Budesonide for Inflammation in Functional Dyspepsia

We are studying whether Budesonide can help reduce inflammation and improve symptoms in patients with functional dyspepsia. This trial will also look at its effects on quality of life and emotional well-being.

Functional Dyspepsia3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementGastroenterology

Golcadomide for Brain Lymphoma: A Phase 2 Study

We are studying the effectiveness of golcadomide in patients with relapsed or refractory large B-cell lymphoma in the brain. The goal is to see if it can help achieve remission and improve overall health.

Diffuse Large B-Cell LymphomaSecondary Central Nervous System LymphomaRelapsed Primary Large B-Cell Lymphoma of the Central Nervous System1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Myeloma: Isatuximab Combination Therapy

We are studying a new treatment combining isatuximab with other medications for patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see how effective and safe this treatment is, and how it impacts patients' lives.

Newly Diagnosed Transplant Ineligible Multiple Myeloma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

ELGN-2112 for Intestinal Malabsorption in Preterm Infants

We are studying whether ELGN-2112 can help preterm infants with intestinal malabsorption achieve full feeding sooner and reduce the risk of serious complications. This trial compares the new treatment to a placebo to assess its safety and effectiveness.

Intestinal Malabsorption>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Alcohol Use Disorder: Sunobinop Study

We are testing whether Sunobinop can help reduce heavy drinking days for individuals with alcohol use disorder. This study aims to understand its effects on overall alcohol consumption and cravings.

Alcohol Use Disorder≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPsychiatry

Heart Procedure: Comparing Blood Thinners

We are studying how two different blood-thinning treatments affect blood clotting in patients undergoing closure of heart defects. This may help us understand which treatment is safer and more effective after the procedure.

Patent Foramen Ovale (PFO) / Atrial Septum Defect (ASD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Menstrual Migraine: Rimegepant Study

We are investigating whether Rimegepant can help prevent menstrual migraines in women aged 18 to 45. This study compares its effects to a placebo to see if it reduces migraine frequency and improves quality of life.

Menstrual Migraine6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsNeurology

Ulcerative Colitis: Encapsulated Stool Microbiome Study

We are investigating whether long-term treatment with encapsulated stool microbiome can improve symptoms in people with active ulcerative colitis. This study compares the treatment to a placebo to assess its effectiveness.

Active Ulcerative Colitis≤3 monthsConfirmation phase (III)Investigational MedicinesGastroenterologyInfectious Diseases

Multiple Myeloma: ABBV-453 Treatment Study

We are studying the safety and effects of ABBV-453, alone or with other treatments, for adults with multiple myeloma. This research aims to understand how well it works and how it is tolerated by patients.

Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Bipolar Depression: Lithium vs. Cariprazine

We are comparing the effectiveness of lithium and cariprazine for treating acute depressive episodes in people with bipolar disorder. The goal is to find out which medication may lead to better improvements in mood.

Depressive Episode in Bipolar Disorder≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Refractory Solid Tumors: Propranolol and Vinorelbine Study

We are testing a combination of Propranolol and Vinorelbine in children and teenagers with hard-to-treat solid tumors. The study aims to find the safest dose and evaluate how well this treatment works over time.

Malignant GliomaMalignant Solid TumorDesmoid Tumor>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Schizophrenia Treatment: Cannabidiol vs. Placebo

We are studying whether adding cannabidiol to standard antipsychotic treatment helps improve recovery in early schizophrenia. The trial will also look at safety and changes in mental and social functioning.

Remitted Schizophrenia1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry